Modality
Nanobody
MOA
KRASG12Di
Target
TNFα
Pathway
Cell Cycle
DLBCL
Development Pipeline
Preclinical
~Sep 2017
→ ~Dec 2018
Phase 1
Mar 2019
→ Mar 2028
Phase 1Current
NCT06144683
1,568 pts·DLBCL
2019-03→2028-03·Recruiting
1,568 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-08-058mo agoEnrollment Complete· DLBCL
2028-03-172.0y awayPh2 Data· DLBCL
Trial Timeline
2019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
P1/2
Recruit…
Catalysts
Enrollment Complete
2025-08-05 · 8mo ago
DLBCL
Ph2 Data
2028-03-17 · 2.0y away
DLBCL
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06144683 | Phase 1/2 | DLBCL | Recruiting | 1568 | DAS28 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| Zanusertib | AbbVie | Approved | PCSK9 | |
| ABB-3951 | AbbVie | Phase 2/3 | TNFα | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| GIL-6239 | Gilead Sciences | Phase 2 | TNFα | |
| MRN-8225 | Moderna | Preclinical | TNFα | |
| Sovanaritide | Argenx | Phase 3 | TNFα | |
| 369-4107 | Hansoh Pharma | Phase 2 | TNFα | |
| VKT-4052 | Viking Therapeutics | Phase 2/3 | TNFα |